Tarceva approved for non-small cell lung cancer after failure of chemotherapy

Wednesday, September 16th, 2009 at 11:34 am

December 24th, 2004 OSI Pharmaceuticals, Inc., (NASDAQ:OSIP) and Genentech, Inc., (NYSE:DNA) announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung